Substance P Peptide Promotes Diabetic Wound Healing by Switching Inflammation from Chronic to Healing Mode

Researchers used multiple animal models: diabetic mice and rabbits received exogenous Substance P treatment on skin wounds, while genetically modified mice lacking either Substance P or its receptor (neurokinin-1 receptor) were used to confirm the peptide's role in healing. The team measured SP gene expression, neutral endopeptidase levels, inflammatory markers, and macrophage phenotype (M1 vs. M2 polarization) throughout the wound healing process.

Diabetic foot ulcers affect millions of people worldwide and are a leading cause of non-traumatic limb amputation. Current treatments are often inadequate because they don't address the underlying inflammatory dysfunction. This research identifies a specific molecular mechanism — Substance P depletion — driving chronic wound inflammation in diabetes, and demonstrates that replacing this peptide can restore normal healing. This could lead to topical peptide therapies for diabetic wounds.

This study contributes to a growing understanding that neuropeptides play critical roles in wound healing beyond their traditional nervous system functions. The finding that diabetic skin has a specific Substance P deficit adds to the evidence that diabetes disrupts the neuro-immune crosstalk necessary for tissue repair. It also supports the broader concept of peptide-based wound therapeutics as an alternative to growth factor therapies that have shown limited clinical success.

This study was conducted entirely in animal models (mice and rabbits), which heal differently from humans — particularly in skin structure and immune response. Specific dosing, delivery methods, and long-term safety of Substance P treatment were not detailed in the abstract. The study also did not examine whether Substance P treatment could work in established chronic wounds versus newly created experimental wounds.